Table 6

Relationship between ACF SMAD4 expression and adenoma recurrence

Patients with intact SMAD by IHC, n = 10Patients with deficient SMAD by IHC, n = 11
Patients with recurrent adenomas at year 1 and/or year 3, n (%)8 (80)2 (18)
Risk ratio (95% confidence interval)10.23 (0.06-0.83)*
P0.01
Patients with intact SMAD by IHC, n = 10Patients with deficient SMAD by IHC, n = 11
Placebo twice daily (n = 3)Celecoxib twice daily (n = 7)Placebo twice daily (n = 4)Celecoxib twice daily (n = 7)
Patients with recurrent adenomas at year 1 and/or year 3, n (%)3 (100)5 (71)1 (25)1 (14)
  • *The risk ratio (95% confidence interval) for risk of recurrent adenomas by SMAD4 status controlling for treatment status was 0.22 (0.06-0.80) with Breslow's test for homogeneity of P = 0.49.